Novo Nordisk A/S (NYSE:NVO) Now Covered by HSBC

Equities research analysts at HSBC started coverage on shares of Novo Nordisk A/S (NYSE:NVO – Get Free Report) in a report issued on Friday, MarketBeat reports. The firm set a “buy” rating on the stock.

NVO has been the topic of several other research reports. Credit Suisse Group raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Thursday, April 13th. StockNews.com started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock.

Get Novo Nordisk A/S alerts:

Novo Nordisk A/S Trading Up 2.1 %

NYSE NVO opened at $160.14 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.67 and a current ratio of 0.86. The firm has a market cap of $359.32 billion, a PE ratio of 42.14, a P/E/G ratio of 1.41 and a beta of 0.47. Novo Nordisk A/S has a one year low of $95.02 and a one year high of $172.97. The firm’s fifty day moving average is $161.39 and its two-hundred day moving average is $152.44.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its quarterly earnings data on Thursday, May 4th. The company reported $1.27 EPS for the quarter, meeting analysts’ consensus estimates of $1.27. The company had revenue of $7.69 billion for the quarter, compared to analyst estimates of $7.86 billion. Novo Nordisk A/S had a net margin of 32.53% and a return on equity of 77.39%. Analysts expect that Novo Nordisk A/S will post 5.07 earnings per share for the current year.

Institutional Trading of Novo Nordisk A/S

Institutional investors have recently added to or reduced their stakes in the stock. Schubert & Co lifted its holdings in shares of Novo Nordisk A/S by 96.2% in the fourth quarter. Schubert & Co now owns 204 shares of the company’s stock valued at $28,000 after purchasing an additional 100 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $28,000. Tsfg LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $30,000. RFP Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $30,000. Finally, Sageworth Trust Co purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $31,000. Hedge funds and other institutional investors own 6.30% of the company’s stock.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.

Recommended Stories

• Five stocks we like better than Novo Nordisk A/S
• MarketBeat Week in Review – 7/10 – 7/14
• Wells Fargo’s Earnings, Why Markets Are Loving The Stock
• Citigroup Leads Banking Earnings, What’s Next?
• BlackRock Kicks Off Financials Earnings Season, Gauge To Markets
• JPMorgan Chase Is In Reversal But Don’t Chase It Higher 

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.